Processa Pharmaceuticals, Inc. Contracts & Agreements
71 Contracts & Agreements
- Business Finance (40 contracts)
- Business Formation (1)
- Business Operations (1)
- Human Resources (8)
- Intellectual Property (10)
- Real Estate (1)
- Uncategorized (10)
- Employment Agreement dated July 16, 2024 by and between Russell Skibsted and Processa Pharmaceuticals, Inc (Filed With SEC on July 17, 2024)
- Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 29, 2024)
- Warrant issued to Spartan Capital, Inc (Filed With SEC on March 29, 2024)
- Form of Securities Purchase Agreement, dated January 26, 2024, by and between Processa Pharmaceuticals, Inc. and each of the Purchasers (as defined therein) (Filed With SEC on January 30, 2024)
- Form of Placement Agent Warrant (Filed With SEC on January 30, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on January 30, 2024)
- Form of Common Warrant (Filed With SEC on January 30, 2024)
- Form of Placement Agent Warrant (Filed With SEC on January 22, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on January 22, 2024)
- Form of Common Warrant (Filed With SEC on January 22, 2024)
- Form of Securities Purchase Agreement (Filed With SEC on January 22, 2024)
- Employment Agreement dated August 8, 2023 by and between George Ng and Processa Pharmaceuticals, Inc (Filed With SEC on August 8, 2023)
- First Amendment to Consulting Agreement with Spartan Capital Securities, LLC (Filed With SEC on March 30, 2023)
- Form of Securities Purchase Agreement, dated February 9, 2023, by and between Processa Pharmaceuticals, Inc. and each of the Investors (as defined therein) (Filed With SEC on February 13, 2023)
- First Amendment to Lease Agreement for Processa Pharmaceuticals, Inc (Filed With SEC on November 8, 2022)
- Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 30, 2022)
- Registration Rights Agreement, dated March 23, 2022, by and between Processa Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on March 24, 2022)
- Purchase Agreement, dated March 23, 2022, between Processa Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on March 24, 2022)
- Equity Distribution Agreement, dated August 20, 2021, by and among Processa Pharmaceuticals, Inc. and Oppenheimer & Co. Inc (Filed With SEC on August 20, 2021)
- License Agreement dated June 16, 2021 (Filed With SEC on June 17, 2021)
- Addendum No. 1 to the Aposense Ltd. License Agreement (Filed With SEC on March 25, 2021)
- Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 25, 2021)
- Form of Placement Agent Warrant (Filed With SEC on February 18, 2021)
- Registration Agreement dated February 16, 2021 (Filed With SEC on February 18, 2021)
- Securities Purchase Agreement dated February 16, 2021 (Filed With SEC on February 18, 2021)
- Employment Agreement, dated October 6, 2020, between Processa Pharmaceuticals and R. Michael Floyd (Filed With SEC on October 13, 2020)
- Underwriting Agreement, dated as of October 1, 2020, by and among the Company, Craig-Hallum Capital Group LLC and Benchmark Company, LLC, as representatives of several Underwriters (Filed With SEC on October 6, 2020)
- License Option Agreement with CoNCERT (Filed With SEC on September 17, 2020)
- Employment Agreement dated September 5, 2018, between Processa and James Stanker (Filed With SEC on September 17, 2020)
- Amended and Restated 2011 Equity Incentive Plan (Filed With SEC on September 17, 2020)
- Form of Warrant (Filed With SEC on September 17, 2020)
- Form of Subscription Agreement for Senior Convertible Notes (Filed With SEC on September 17, 2020)
- Form of Underwriting Agreement (Filed With SEC on September 17, 2020)
- Asset Purchase Agreement. Dated October 2, 2017, among the Company, Promet Therapeutics LLC and Processa Therapeutics LLC (Filed With SEC on September 17, 2020)
- Specimen of Common Stock Certificate (Filed With SEC on September 17, 2020)
- Warrant issued to PoC Capital, LLC (Filed With SEC on September 17, 2020)
- Warrants issued to Boustead Securities (Filed With SEC on September 17, 2020)
- Amendment to License Agreement and Securities Purchase Agreement with CoNCERT Pharmaceuticals (Filed With SEC on September 17, 2020)
- Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan (Filed With SEC on September 17, 2020)
- License Agreement with Elion Oncology, Inc (Filed With SEC on September 17, 2020)
- Share Issuance Agreement pursuant to License Agreement with Yuhan Corporation (Filed With SEC on September 17, 2020)
- License Agreement with Yuhan Corporation (Filed With SEC on September 17, 2020)
- License Agreement with Aposense, Ltd. dated May 24, 2020 (Filed With SEC on September 17, 2020)
- License Agreement with Akashi Therapeutics, Inc. dated August 29, 2019 (Filed With SEC on September 17, 2020)
- Line of Credit Agreement dated September 20, 2019 between Processa Pharmaceuticals and CorLyst, LLC (Filed With SEC on September 17, 2020)
- Line of Credit Agreement dated September 20, 2019 between Processa Pharmaceuticals and DKBK Enterprises, LLC (Filed With SEC on September 17, 2020)
- License Agreement by and between Processa Pharmaceuticals and Elion Oncology dated August 23, 2020 (Filed With SEC on August 27, 2020)
- License Agreement by and between Processa Pharmaceuticals, Inc. and Yuhan Corporation, dated August 19, 2020 (Filed With SEC on August 20, 2020)
- Share Issuance Agreement by and between Processa Pharmaceuticals, Inc. and Yuhan Corporation, dated August 19, 2020 (Filed With SEC on August 20, 2020)
- Promissory Note, dated May 1, 2020, with Processa Pharmaceuticals, Inc. and Bank of America, N.A., received by the company under the Small Business Administration Paycheck... (Filed With SEC on July 17, 2020)
- Form of 8% Senior Convertible Notes (Filed With SEC on December 13, 2019)
- Line of Credit Agreement dated September 20, 2019 between Processa Pharmaceuticals and CorLyst, LLC (Filed With SEC on October 3, 2019)
- Amendment to the Agreement between PoC Capital and Processa Pharmaceuticals, Inc. dated September 30, 2019 (Filed With SEC on October 3, 2019)
- Line of Credit Agreement dated September 20, 2019 between Processa Pharmaceuticals and DKBK Enterprises, LLC (Filed With SEC on October 3, 2019)
- Pledge Agreement dated May 25, 2018, by and between Processa Pharmaceuticals, Inc. and PoC Capital, LLC (Filed With SEC on October 9, 2018)
- Employment Agreement, dated September 5, 2018, between Processa Pharmaceuticals and James Stanker (Filed With SEC on September 10, 2018)
- Form of Warrant (Filed With SEC on May 21, 2018)
- Boustead Engagement Letter (Filed With SEC on May 21, 2018)
- Form of Purchase Agreement (Filed With SEC on May 21, 2018)
- Convertible Note (Filed With SEC on April 16, 2018)
- Amendment to License Agreement and Securities Purchase Agreement with CoNCERT Pharmaceuticals (Filed With SEC on April 16, 2018)
- License Option Agreement with CoNCERT (Filed With SEC on April 16, 2018)
- Lock-Up Period (Filed With SEC on October 12, 2017)
- Lock-Up Period (Filed With SEC on October 12, 2017)
- ACQUISITION AGREEMENT By and Among HEATWURX, INC., a Delaware corporation PROCESSA THERAPEUTICS, LLC a Delaware limited liability company and PROMET THERAPEUTICS, LLC a Delaware... (Filed With SEC on October 5, 2017)
- PROMISSORY NOTE EXTENSION AGREEMENT ADDENDUM TO NOTES UNDER LOAN AGREEMENT: SENIOR SECURED LOAN AGREEMENT 2.16.15 Extended to February 15, 2016 (Filed With SEC on August 19, 2015)
- HEATWURX, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on March 27, 2014)
- CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES D 8% CONVERTIBLE PREFERRED STOCK OF HEATWURX, INC. (As amended on November 20, 2013) Pursuant to Section 151 of the... (Filed With SEC on March 27, 2014)
- SUBORDINATION AGREEMENT (Filed With SEC on May 23, 2013)
- SENIOR LOAN AGREEMENT (Filed With SEC on May 23, 2013)
- SETTLEMENT AND MUTUAL RELEASE AGREEMENT (Filed With SEC on January 11, 2013)
